Personalis Files SEC Form 425 Signaling Active M&A Transaction

Personalis ran 10,384 cancer genomics tests in the second quarter of 2026. That is up 33% from the prior quarter. On July 20, 2026, Tempus AI agreed to buy the company for approximately $1.5 billion in stock. The test volume growth and the deal price are not separate facts. One explains the other. Understanding that connection is the whole point of this essay.

The thesis here is simple. Tempus AI is not buying a testing business. It is buying a data infrastructure asset that happens to generate revenue through tests. The $1.5 billion price tag, the all-stock structure, and the specific deal conditions all make more sense once you accept that framing. And for institutional holders, M&A practitioners, and corporate development teams watching this category, the deal sets a pricing reference that will ripple through comparable assets before the year is out.

The Signal: What the Filing Confirms

Personalis filed a Form 425 with the SEC on July 20, 2026. That filing is a mandatory disclosure. It is triggered when a company makes communications in connection with a live business combination. You do not file a Form 425 to speculate. You file it because a deal is real and disclosure is required by law.

I have tracked this pattern across multiple transactions this cycle. The Perceptive Capital Solutions filing in May 2026 preceded the Freenome SPAC announcement. The Bleichroeder filing on the Pasqal quantum computing deal followed the same sequence. In each case, the Form 425 was the operative signal, not the press release that came after. The press release is for journalists. The filing is for investors.

In this case, the filing confirmed what Business Wire reported directly from the company: Tempus AI has entered into a definitive agreement to acquire Personalis. The deal is structured as a stock-for-stock merger. According to StockTitan's summary of the SEC filing, Personalis shareholders will receive Tempus Class A shares at a fixed exchange ratio. The deal includes a hard condition: if Tempus Class A shares trade below $46.00 through the closing window, Personalis has the right to terminate. Mutual termination fees are set at $76.8 million on each side. The outside closing date, per the filing summary on StockTitan, is April 20, 2027, with the companies targeting late 2026 or early 2027 subject to stockholder votes and regulatory clearance.

Levin Associates reported the per-share consideration at $16.25 for Personalis common stockholders, representing a total enterprise value of $1.5 billion net of Tempus's existing ownership interest in the company. Cooley, which advised Personalis on the transaction, cited a figure closer to $1.9 billion on an equity value basis. The difference reflects how you treat Tempus's pre-existing stake. The $1.5 billion enterprise value is the cleaner number for comparables work.

The full exchange ratio and pro forma financials will appear in the S-4 registration statement that Tempus files with the SEC. That document is the primary diligence source for institutional holders deciding how to vote. It is not public yet. Until it is, the Form 425 is what you have, and it is enough to confirm the deal is live.

The Asset: What Tempus Is Actually Buying

Personalis describes itself as a leader in advanced genomics for precision oncology. That is accurate but incomplete. The more precise description is this: Personalis generates longitudinal genomic data from cancer patients, and that data is the kind that trains and validates clinical AI models.

The core product is the NeXT Personal platform, which detects minimal residual disease, or MRD. MRD testing measures whether cancer cells remain in a patient's body after treatment. It is a sensitive, high-value test. It requires deep sequencing of tumor DNA and circulating tumor DNA from blood. Each test produces a rich genomic dataset tied to a specific patient's cancer profile over time.

That longitudinal data is the asset. A single MRD test is useful clinically. Ten thousand MRD tests from oncology patients, tracked across treatment cycles, with outcomes data attached, is a training corpus for clinical AI. Tempus, which already operates an AI-enabled precision oncology platform across hospital networks, knows exactly what that corpus is worth.

The Q2 2026 test volume of 10,384, up 33% sequentially, matters because it shows the data generation rate is accelerating. The faster the tests run, the faster the training data accumulates. For Tempus, acquiring Personalis now rather than in twelve months means acquiring the data before it becomes more expensive. The growth rate is not just a revenue story. It is a data scarcity argument.

Personalis also received UKCA marking for its NeXT Personal Dx test just one week before the deal announcement, according to Business Wire. That regulatory clearance enables clinical use in England, Wales, and Scotland. The company had also received Class A CE-IVD marking under the EU's In Vitro Diagnostic Regulation for its blood collection kits in June 2026, as reported by Investing.com. These are not coincidental timing events. Regulatory clearances in major markets increase the addressable data generation opportunity. They also make the asset harder to replicate quickly. A competitor cannot simply build an equivalent platform overnight if the regulatory pathway alone takes years.

This is not a pure revenue acquisition. It is a data infrastructure acquisition structured as a clinical services deal. The distinction matters for how you model synergies. Revenue synergies are real but secondary. The primary value creation is in what Tempus can do with Personalis's proprietary data stack once it is integrated into the Tempus clinical AI platform.

Deal Structure and Risk Factors

The all-stock structure is the right choice for a deal of this type, and it tells you something about how both boards view the relative value of their companies.

When an acquirer pays in stock rather than cash, it is saying: our shares are worth holding. It is also saying: we want the target's shareholders to participate in the upside of the combined entity. For Personalis shareholders, the all-stock consideration means they are not cashing out. They are converting into Tempus shareholders at a fixed ratio. That is a bet on Tempus's ability to execute the integration and grow the combined platform.

The $46.00 floor on Tempus Class A shares is the most important mechanical detail in this deal. It is a hard termination right for Personalis. If Tempus shares trade below that level for a sustained period through the closing window, Personalis can walk. That provision protects Personalis shareholders from a scenario where TEM stock deteriorates and the fixed exchange ratio delivers less value than the headline price implies. Track TEM's share price against that floor every day until closing. It is the live risk variable in this structure.

The mutual $76.8 million termination fees deserve attention. On a sub-$2 billion all-stock deal, symmetric break fees at roughly four to five percent of deal value signal balanced negotiating leverage. Neither side holds a structural advantage in a walk scenario. Both boards have skin in the deal closing. That is a clean special committee process on both sides, and it reduces the probability of a late-stage renegotiation.

Regulatory clearance is required under Hart-Scott-Rodino. The deal touches genomic data, clinical AI, and healthcare services. A second request from the DOJ or FTC would extend the review period and push the closing target into 2027. Given the current regulatory environment around health data and AI, a second request is a non-trivial risk. It is not the base case, but it is worth monitoring. The outside closing date of April 20, 2027 gives the parties enough runway to absorb a second request without triggering a termination.

Comparable Pricing: What This Print Does to the Sector

A confirmed $1.5 billion enterprise value for a company running roughly 10,000 quarterly tests with 33% sequential volume growth is now the reference price for MRD and cancer genomics data platforms. Full stop.

Before this deal, acquirers in biopharma, health data, and enterprise AI had limited public comps for MRD-focused genomic platforms. Private transactions in this space are sparse and often not fully disclosed. This deal gives M&A teams a defensible number for fairness opinions on comparable targets. It also gives allocators a framework for repricing positions in similar companies.

The implied multiple on test volume is what matters most. If you divide the $1.5 billion enterprise value by the annualized test run rate implied by Q2 2026 volume, you get a sense of what the market is paying per test, per year, for a platform with this growth trajectory. That math will appear in the Tempus S-4 fairness opinion. Do not wait for the S-4 to run it yourself.

For private genomic AI platforms in similar categories, this print is a ceiling and a floor simultaneously. It is a ceiling in the sense that not every MRD platform will command this multiple. Data exclusivity, regulatory clearances, and biopharma customer concentration all affect the discount. It is a floor in the sense that any acquirer trying to lowball a comparable target now has a public comp to argue against. The Tempus-Personalis deal has changed the negotiating environment for this category.

According to TipRanks, the deal will combine Personalis's tumor-informed MRD technology with Tempus's AI and precision oncology platform to improve cancer monitoring and support biomarker discovery. That integration thesis is credible. Tempus already processes oncology data at scale. Adding a validated MRD workflow and the associated longitudinal data corpus is additive, not redundant.

The Bear Case and Why It Does Not Hold

Skeptics will argue that $1.5 billion is too much to pay for a company running 10,000 tests per quarter with no disclosed path to profitability, in a regulatory environment where genomic data faces increasing scrutiny around patient privacy and cross-border data flows. They will point to the all-stock structure as evidence that Tempus itself is not willing to commit hard cash, which implies uncertainty about the combined entity's near-term cash generation. They will also note that the exchange ratio is not yet public, meaning Personalis shareholders are voting on a deal without knowing the precise conversion terms. That is a legitimate governance concern.

The rebuttal is grounded in the evidence. Personalis received UKCA marking in Great Britain just one week before the deal announcement and EU CE-IVD marking in June 2026, according to Business Wire and Investing.com. A company with deteriorating fundamentals does not expand its regulatory footprint across two major markets in the month before a sale. The regulatory clearances are proof of platform quality, not distress.

Reader Relevance

If you are a long-only portfolio manager with precision medicine or genomic AI exposure: Your PSNL position converts to TEM shares at a fixed ratio with a $46.00 floor. Model TEM share price risk through the closing window now, before the S-4 lands. The fairness opinion in that document will tell you whether the exchange ratio reflects fair value, but by the time most retail holders read it, the institutional vote will already be forming.

If you are a corporate development lead at a biopharma or health data platform: The $1.5 billion enterprise value on a 33% sequential growth MRD platform is your new comp for fairness opinions on comparable targets. If you are running a dual-track process or preparing a bid for a similar asset, the symmetric $76.8 million break fee structure and the $46.00 floor mechanism are your negotiating anchors. Reuters confirmed the deal terms on July 20, 2026. Your counterparties have already seen them.

If you are an M&A lawyer advising on life sciences combinations: The mutual termination fee at roughly four to five percent of deal value on a sub-$2 billion all-stock transaction is a reference data point for fee negotiations on comparable deals. Symmetric break fees at this level signal a clean process. If your client is pushing for asymmetric fees on a deal of similar size and structure, this transaction gives the other side a strong counter-argument.

What to Watch Next

First, the Tempus AI S-4 or F-4 registration statement on SEC EDGAR. That document contains the full exchange ratio, the pro forma financials, and the fairness opinion. It is the primary diligence document for institutional holders deciding how to vote. File it in your calendar. The moment it drops, the exchange ratio becomes public and the market can price the deal precisely.

Second, any HSR second request from the DOJ or FTC. A second request extends the antitrust review period by a minimum of thirty days and often longer. Given the overlap in genomic data and clinical AI between Tempus and Personalis, a second request is possible. If one arrives, the closing timeline shifts to 2027 and the $46.00 floor provision becomes more consequential as TEM share price has more time to move.

Third, Tempus AI's share price relative to the $46.00 floor. This is the live risk variable through the closing window. If TEM trades below $46.00 for a sustained period, watch for one of three outcomes: a renegotiated exchange ratio, a collar adjustment to protect deal value, or a termination fee trigger. The outside closing date of April 20, 2027 gives both parties time to manage this risk, but the floor is a hard condition and the market will test it.

The deeper question is whether the market will assign terminal value to Personalis's data exclusivity or only to its test volume. Those are two very different valuation frameworks, and the proxy will force institutional holders to choose between them.